Evidence map›Paper›PMID 35052942›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Impact of a Novel Anticoccidial Analogue on Systemic

Hang Thi Nguyen, Henrietta Venter, Lucy Woolford, Kelly Young, Adam McCluskey, Sanjay Garg, Stephen W Page, Darren J Trott, Abiodun David Ogunniyi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 66% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Hang Thi NguyenAustralian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, SA 5371, Australia.ORCID 0000-0002-6313-9371
Henrietta VenterHealth and Biomedical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0001-5569-7755
Lucy WoolfordSchool of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy Campus, Roseworthy, SA 5371, Australia.ORCID 0000-0001-7271-2937
Kelly YoungChemistry, School of Environmental & Life Sciences, University of Newcastle, Callaghan, NSW 2308, Australia.
Adam McCluskeyChemistry, School of Environmental & Life Sciences, University of Newcastle, Callaghan, NSW 2308, Australia.ORCID 0000-0001-7125-863X
Sanjay GargClinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0001-7253-2629
Stephen W PageNeoculi Pty Ltd., Burwood, VIC 3125, Australia.ORCID 0000-0001-5312-2149
Darren J TrottAustralian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, SA 5371, Australia.
Abiodun David OgunniyiAustralian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, SA 5371, Australia.ORCID 0000-0001-9308-5629
The University of Adelaide · AUUniversity of Newcastle Australia · AUUniversity of South Australia · AUVietnam National University of Agriculture · VN

Funding

Australian Research Council LP110200770
6 · The paper itself

Abstract

In this study, we investigated the potential of an analogue of robenidine (NCL179) to expand its chemical diversity for the treatment of multidrug-resistant (MDR) bacterial infections. We show that NCL179 exhibits potent bactericidal activity, returning minimum inhibitory concentration/minimum bactericidal concentrations (MICs/MBCs) of 1-2 µg/mL against methicillin-resistant

Indexed as

antibiotic combinationbioluminescencecolistinGram-negative bacteriaGram-positive bacteriamultidrug-resistanceNCL179robenidineStaphylococcus aureus

Identifiers

PMID35052942
PMCPMC8773087
OpenAlexW4205572435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.